Metaplexis japonica extract nanoparticle composition, preparation method and application

Abstract

The invention provides metaplexis japonica extract nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nanoparticle is composed of a capsule core filler, a carrier material, a surfactant, an emulsifier and water, the capsule core filler is metaplexis japonica extract; the carrier material is polyethylene glycol-polylactic acid. The preparation method comprises the following steps: preparing polyethylene glycol-polylactic acid (PEG-PLLA) from L-LA, PEG and stannous octoate according to a molar ratio of 100: 1: 1, and preparing the PC coated PEG-PLLA nano-particles according to a weight ratio of PEG-PLLA to PC of 1: 3. According to the PC-coated PEG-PLLA NPs, the average particle size is (113.1 + / -2.5) nm, the PDI is (0.173 + / -0.020), the potential is (-46.7 + / -1.9) mV, and meanwhile, the PC-coated PEG-PLLA NPs has good stability. As a medicine for treating autoimmune hepatitis (AIH), the compound has a relatively high value.

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to a photinia scabra extract nanoparticle composition, a preparation method and applications. Background Art

[0002] The liver is a solid organ with unique immune properties. It plays a key role in the maintenance of immune response, regulation and tolerance. Despite this, the liver is susceptible to a variety of diseases, especially hepatitis. Among them, autoimmune hepatitis (AIH) is a chronic liver inflammatory disease mediated by abnormal autoimmune reactions. It mainly attacks the female population and has diverse clinical manifestations. Current statistics show that the incidence of AIH is between 4 and 42 cases per 100,000 people, and this rate is on the rise. Currently, in the treatment of autoimmune hepatitis (AIH), glucocorticoids are commonly used drugs that can effectively inhibit abnormal immune responses. However, some patients do not respond well to glucocorticoid treatment and may suffer serious adverse reactions. In view of this, the development of new therapeutic drugs with low toxicity and high efficiency has become an urgent task and core focus in the field of modern medical research.

[0003] Traditional Chinese medicine is widely used to treat liver diseases, including autoimmune hepatitis (AIH), to alleviate symptoms and reduce hormone side effects. Researchers Galani and BRT et al. found that the water extract of Psoralea corylifolia has antioxidant and anti-inflammatory effects, which is beneficial to the liver, as reflected in lowering ALT, increasing SOD, CAT, GSH levels, and reducing MDA and TNFα. Psoralea corylifolia is recorded in the "Xinhua Compendium of Materia Medica" and has the effect of clearing heat and detoxifying. It is used to treat hepatitis and eye diseases and is distributed in many places in China. Summary of the invention

[0004] The first purpose of the present invention is to provide a Pholiota extract nanoparticle composition in view of the above-mentioned problems existing in the prior art. The technical problem to be solved by the present invention is to provide a Pholiota extract nanoparticle composition with uniform and controllable nanoparticle size, good in vitro and in vivo stability, and the ability to improve therapeutic efficacy.

[0005] The purpose of the present invention can be achieved through the following technical scheme: a nanoparticle composition of Pholiotaepus extract, characterized in that it includes a capsule core filler, a carrier material, a surfactant, an emulsifier and an aqueous phase.

[0006] Furthermore, the capsule core filling material is PC, which is the inner oil phase, i.e., the O1 phase;

[0007] Further, the carrier material is polyethylene glycol-polylactic acid, which is the outer oil phase, i.e., the O2 phase;

[0008] Furthermore, the aqueous phase is solvent distilled water, i.e., phase W;

[0009] Further, the surfactant is one or more of Span20, Span40, Span60, Span80, and Span85;

[0010] Furthermore, the emulsifier is an O / W type emulsifier, selected from one or more of sodium dodecyl sulfate (SDS), Tween 80, and Poloxamer 188.

[0011] The nanoparticles have an average particle size of 113.1±2.5 nm, a polydispersity index PDI of 0.173±0.020, an electric potential of -46.7±1.9 mV, and good stability.

[0012] Polyethylene glycol-polylactic acid (PEG-PLLA) was prepared by mixing L-LA, PEG and stannous octoate in a molar ratio of 100:1:1; PC@PEG-PLLA nanoparticles were prepared by mixing PEG-PLLA and PC in the nanoparticles in a mass ratio of 1:3;

[0013] The second object of the present invention is to provide a targeted extraction process for Chinese medicinal materials, specifically the Herba Lycopodii extract in the above composition.

[0014] The extraction process includes the following steps:

[0015] (1) extracting the medicinal material of Plectranthus radiata with 40-80% by weight ethanol by reflux, heating at about 55° C., refluxing for 2-3 hours, and concentrating the extract at 60-70° C. by rotary evaporation to obtain a crude extract;

[0016] (2) adding an appropriate amount of water to the extracted extract, mixing, adding an equal volume of petroleum ether, shaking, extracting 3-5 times, evaporating and concentrating to dryness to obtain a petroleum ether partial extract; adding an equal volume of ethyl acetate, shaking, extracting 3-5 times, evaporating and concentrating to dryness to obtain an extract;

[0017] (3) The ethyl acetate extract was appropriately dissolved in dichloromethane reagent, stirred and ground with 200-300 mesh silica gel particles to form a fine powder, and dry-loaded on a silica gel column, and eluted with dichloromethane-methanol (volume ratio of 50:1), dichloromethane-methanol (volume ratio of 10:1), and dichloromethane-methanol (volume ratio of 4:1) gradient eluents in sequence;

[0018] (4) Take out an appropriate amount of the target fraction, dissolve it in an appropriate amount of dichloromethane, mix it with 200-300 mesh silica gel particles, stir it, and dry-load it onto a silica gel column. Elute it in sequence with petroleum ether-acetone (volume ratio of 3:1), petroleum ether-acetone (volume ratio of 2:1), and petroleum ether-acetone (volume ratio of 1:1), and then elute it with dichloromethane-methanol (volume ratio of 30:1) gradient elution to obtain the Pholiota pectinata extract PC.

[0019] The third object of the present invention is to provide a method for preparing the above-mentioned Pholiotaepus extract nanoparticles, characterized in that it comprises the following steps:

[0020] (1) An appropriate amount of L-lactide (L-LA) was recrystallized 3-5 times with ethyl acetate, and PEG-PLLA polymer was prepared by ring-opening polymerization using PEG as an initiator and stannous zincate as a catalyst;

[0021] (2) PC was dissolved in anhydrous ethanol as the O1 phase, PEG-PLLA was dissolved in dichloromethane (CHCl2) as the O2 phase, and then 1 drop of Span80 was added. The PC solution and the solution containing PEG-PLLA were thoroughly mixed and the mixture was placed in a high-speed shear dispersing emulsifier to ensure complete emulsification;

[0022] (3) gradually adding the crude emulsified mixture into the SDS solution, and further treating the emulsified mixture with an ultrasonic cell disruptor;

[0023] (4) The mixed solution is stirred magnetically at room temperature until the organic solvent is completely evaporated and solidified to form nanoparticles.

[0024] As described in the above step (1), the recrystallized L-LA, PEG and stannous octoate are weighed in a molar ratio of 100:1:1; under nitrogen protection, the mixture is heated and polymerized in an oil bath at 100-160° C. for 2-5 hours;

[0025] As described in the above step (1), the mass ratio of PEG-PLLA to PC is 1:3;

[0026] The high-speed shearing in the above step (2) is operated at a speed of 10000-28000 rpm for 3-5 minutes;

[0027] The concentration of the SDS solution in the above step (3) is 0.5%-5% by mass, and the optimum is 1%, and the power of the ultrasonic cell disruptor is 30%-50%.

[0028] Beneficial effects of the present invention:

[0029] (1) The PC is extracted from the Chinese medicinal material, Psoralea corylifolia. Compared with some Western medicines, Chinese medicinal extracts usually have fewer side effects and are suitable for long-term use;

[0030] (2) It is relatively safe and suitable for patients who are sensitive to synthetic drugs;

[0031] (3) The carrier material is polyethylene glycol-polylactic acid, which is an amphiphilic polymer with good solubility in both water and oil phases, good biocompatibility, and easy coupling with targeting factors. By selecting an appropriate molecular weight, its mechanical properties, degradation time, etc. can be regulated, thereby preparing a contrast agent with suitable mechanical properties (good toughness, moderate compressive resistance), good stability, and suitable degradation time;

[0032] (4) Compared with traditional drug delivery routes, nanoparticles can cross the vascular endothelium and reach specific targeted lesions under the action of targeting factors;

[0033] (5) The prepared nanoparticles can achieve functional loading; they can load therapeutic drugs for targeted therapy;

[0034] (6) The emulsification-solvent evaporation method can achieve precise control of the particle size of nanoparticles. The prepared nanoparticles have highly uniform particle size, good monodispersity, good in vitro and in vivo stability, and long blood circulation time, which can realize repeated inspection, dynamic monitoring and efficacy evaluation of tumor lesions;

[0035] (7) The emulsification-solvent evaporation method has mild preparation conditions and can avoid destroying the biological activity of targeting factors such as peptides, proteins, and antibodies during preparation;

[0036] (8) The emulsification-solvent evaporation method has good reproducibility in the preparation process. The particle size and PDI value of nanoparticles in different batches fluctuate very little. In addition, the preparation process can be scaled up and is easy to achieve large-scale preparation.

[0037] Traditional drug delivery methods often bring high concentration toxicity and side effects, but nanoparticles can reduce these problems due to their targeting and low systemic distribution. Nanoparticles are of great value in pharmacy, improving drug response, protecting the activity of biological drugs, prolonging mucosal delivery time and improving drug efficacy.

[0038] As one of the applications of the above-mentioned Photinia scoparia extract nanoparticle composition, the Photinia scoparia extract nanoparticles are used to treat autoimmune hepatitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 In the figure, (A) shows the appearance of the nanoparticles, (B) shows the particle size of the nanoparticles, (C) shows the potential of the nanoparticles, (D) shows the stability of the nanoparticles, and (E) shows the electron microscope image of the nanoparticles.

[0040] Figure 2 The liver index and spleen index levels after ConA injection.

[0041] Figure 3 The ultrasonic images of mouse livers, wherein (A) is the ultrasonic image of the blank group, (B) is the ultrasonic image of the model group, and (C) is the ultrasonic image of the drug-treated group.

[0042] Figure 4 Figure 2 shows liver transaminase levels (including alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) after injection of ConA.

[0043] Figure 5 These are micrographs of mouse liver tissue sections stained with hematoxylin and eosin (H&E), where (A) is a micrograph of the control group, (B) is a micrograph of the ConA group, and (C) is a micrograph of the PC@PEG-PLLA NPs group. DETAILED DESCRIPTION

[0044] The following are specific embodiments of the present invention and the accompanying drawings to further describe the technical solution of the present invention, but the present invention is not limited to these embodiments.

[0045] The nanoparticles prepared by the invention can treat autovariant hepatitis. The PC extract of Pholiotaepus rotundus is used as the capsule core filling material, and the biodegradable racemic polylactic acid is used as the carrier material. The nanoparticles are prepared by an emulsification-solvent volatilization method.

[0046] The preparation method is as follows:

[0047] (1) Extracting the medicinal material of Plectranthus chinensis with 80% ethanol in reverse flow to obtain an extract. After degreasing with petroleum ether, the extract was extracted with ethyl acetate. The ethyl acetate portion was subjected to silica gel column chromatography and gradient elution to obtain the Plectranthus chinensis extract PC;

[0048] (2) An appropriate amount of l-lactide (L-LA) was recrystallized three times with ethyl acetate to obtain L-LA recrystallization. PEG-PLLA polymer was prepared by ring-opening polymerization;

[0049] (3) PEG-PLLA was dissolved in dichloromethane (CHCl2) as the O1 phase, and then 1 drop of Span80 was added. PC was dissolved in anhydrous ethanol as the O2 phase. The PC solution and the solution containing PEG-PLLA were thoroughly mixed and the mixture was placed in a high-speed shear dispersing emulsifier to ensure complete emulsification;

[0050] (4) gradually adding the crude emulsified mixture into the SDS solution, and further treating the emulsified mixture with an ultrasonic cell disruptor;

[0051] (5) The mixed solution is magnetically stirred at room temperature until the organic solvent is completely evaporated and solidified to form nanoparticles.

[0052] As described in step (2), the recrystallized L-LA, PEG and stannous octoate are weighed in a molar ratio of 100:1:1. Under nitrogen protection, the mixture is heated in an oil bath at 120°C for 2 hours to promote polymerization;

[0053] As described in step (3), the mass ratio of PEG-PLLA to PC is 1:3;

[0054] In step (3), preferably, the mass ratio of PEG-PLLA to PC is 1:3;

[0055] The high-speed shearing in step (3) is operated at a speed of 20,000 rpm for 3-5 minutes;

[0056] The concentration of the SDS solution in step (4) is 0.5%, and the power of the ultrasonic cell disruptor is 30%;

[0057] The average particle size of the nanoparticles was (113.1±2.5) nm, the PDI was (0.173±0.020), and the potential was (-46.7±1.9) mV;

[0058] The prepared nanoparticles were injected into the established autoimmune hepatitis mouse model. Compared with the model group, the liver index, spleen index, alanine aminotransferase and aspartate aminotransferase levels of the mice in the drug group were significantly reduced, and the degree of hepatocyte necrosis was alleviated. Due to individual differences in mice, there was no significant difference in liver ultrasound examination between the drug group and the model group. PC@PEG-PLLANPs significantly reduced ConA-induced acute liver injury in mice and is worth further study as a drug for the treatment of autoimmune hepatitis (AIH).

[0059] After being injected into the body, the nanoparticles enter the liver and are enriched in the lesion site through the specific binding of targeting factors to liver damaged cells, which can improve the ultrasonic imaging effect of the lesion. The nanoparticles release the drug PC wrapped in them at the lesion site, thereby reducing the severity of liver cell necrosis and enhancing the imaging effect of the lesion site.

[0060] Example 1

[0061] Preparation of Plectranthus chinensis extract nanoparticles:

[0062] (1) Synthesis of PEG-PLLA diblock copolymer

[0063] An appropriate amount of L-lactide (L-LA) was weighed and recrystallized three times with ethyl acetate to obtain recrystallized L-LA. Subsequently, PEG-PLLA polymer was prepared by ring-opening polymerization. The recrystallized L-LA, PEG and stannous octoate were weighed at a molar ratio of 100:1:1. Under nitrogen protection, the mixture was heated in an oil bath at 120°C for 2 hours. After cooling to room temperature, the crude product was dissolved in a small amount of chloroform and precipitated with a small amount of anhydrous ether. The precipitate was then placed in a vacuum oven to dry to obtain the final product of PEG-PLLA.

[0064] (2) Preparation and component analysis of Psoralea corylifolia extract

[0065] The extract of Plectranthus chinensis was obtained by reflux extraction with 80% ethanol. After degreasing with petroleum ether, the extract was extracted with ethyl acetate. The ethyl acetate portion was subjected to silica gel column chromatography and gradient elution to obtain the Plectranthus chinensis extract, which was named PC.

[0066] (3) Preparation of PC@PEG-PLLA nanoparticles

[0067] The synthesis of PC@PEG-PLLA nanoparticles was carried out by emulsification-solvent evaporation method. About 10 mg of PEG-PLLA was dissolved in 1 mL of dichloromethane (CHCl2), followed by adding 1 drop of Span80 and mixing thoroughly. About 30 mg of PC was dissolved in 1 mL of anhydrous ethanol. The PC solution was then thoroughly mixed with the solution containing PEG-PLLA. The resulting mixture was placed in a high-speed shear dispersing emulsifier and run at 20,000 rpm for 3-5 minutes. Subsequently, the crude emulsified mixture was gradually added to 5 mL of 0.5% SDS solution, and the emulsified mixture was further treated with an ultrasonic cell disruptor at 30% power for 5 minutes. Finally, the mixed solution was gently stirred with a magnetic stirrer at room temperature until the organic solvent was completely evaporated.

[0068] Example 2

[0069] The preparation method is the same as in Example 1, except that:

[0070] In step (3), the amount of PEG-PLLA is 5 mg, the amount of PC is 15 mg, the high-speed shear speed is 10000 rpm, the operation is 3 minutes, the SDS concentration is 0.75%, and the cell disruptor power is 15 W;

[0071] Example 3

[0072] The preparation method is the same as in Example 1, except that:

[0073] In step (3), the amount of PEG-PLLA is 15 mg, the amount of PC is 45 mg, the high-speed shear speed is 30,000 rpm, the operation time is 12 minutes, the SDS concentration is 1.5%, and the cell disruptor power is 45 W;

[0074] Example 4

[0075] The preparation method is the same as in Example 1, except that:

[0076] In step (3), the amount of PEG-PLLA is 20 mg, the amount of PC is 60 mg, the high-speed shear speed is 40000 rpm, the operation time is 8 minutes, the SDS concentration is 1%, and the cell disruptor power is 60 W;

[0077] Example 5

[0078] (1) Structural characterization of PEG-PLLA.

[0079] The nanoparticles prepared in Example 1 were subjected to nuclear magnetic resonance measurement of PEG-PLLA using a Bruker Avance III HD 400 MHz spectrometer. The sample was dissolved in deuterated chloroform (CDCl 3 ), and tetramethylsilane (TMS) was used as an internal standard, and the measurement was performed at a resonance frequency of 400 MHz.

[0080] The samples were analyzed by infrared spectroscopy using a PerkinElmer FTIR spectrophotometer. PLLA, PEG, and PEG-PLLA pellets were prepared using the potassium bromide (KBr) pellet method. -1 Up to 500cm -1 The scanning analysis was performed within the wave number range.

[0081] The crystallinity of PLLA, PEG and PEG-PLLA was analyzed by X-ray diffractometer (XRD-6100). The tube voltage was 40 kV, the tube current was 30 mA, the scanning range was 5°-100°, the scanning speed was 10°min, and the scanning step was 0.1°.

[0082] The thermal stability of PLLA, PEG and PEG-PLLA polymers was analyzed by TG209F3 thermogravimetric analyzer. The temperature was increased from 0 to 700 °C at a rate of 20 °C / min under nitrogen.

[0083] (2) Determination of particle size and zeta potential of PC@PEG-PLLA nanoparticles.

[0084] The particle size and zeta potential of PC@PEG-PLLA nanoparticles were measured at 0, 5, 10, 15, 20 and 30 days at 25°C. The average size of the nanoparticles was (113.1±2.5) nm, the polydispersity index (PDI) was (0.173±0.020), and the zeta potential was (-46.7±1.9) mV. Figure 1 As shown, it shows that after being placed at room temperature for one month, the particle size and potential of the nanoparticles change little, and the nanoparticles have good stability during storage.

[0085] (3) Establishment and grouping of AIH mouse model.

[0086] Thirty specific pathogen-free female BALB / c mice were randomly divided into three groups, with 10 mice in each group. The groups were control group (control), model group (ConA) and treatment group (ConA+PC@PEG-PLLA NPs).

[0087] After grouping, each mouse in each group was weighed and its weight was carefully recorded. The mice in the control group were injected with 0.2 mL PBS through the tail vein, and the mice in the model group and the treatment group were injected with ConA dissolved in PBS at a concentration of 15 mg / kg through the tail vein. The treatment group was first administered with PC@PEG-PLLA nanoparticles (0.2 mL, tail vein injection) 16 hours and 8 hours before modeling, and then 1 hour after modeling.

[0088] (4) Liver ultrasound examination

[0089] Under ultrasound imaging, PC@PEG-PLLA NPs in the experimental group significantly reduced liver enlargement in mice. Figure 2 shown.

[0090] (5) Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) determination.

[0091] After 12 hours of administration, blood was collected from the eye sockets of each group of mice and allowed to stand at room temperature for 1 hour. The samples were then centrifuged at 10,000 rpm for 15 minutes at 4°C. The supernatant was collected and the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured.

[0092] Experimental results: 12 hours after Con A induction, the liver of the model group mice was congested and edematous, and the spleen was congested and dark purple. In terms of liver index, the liver index of the experimental group C mice was not significantly affected compared with the control group, but after modeling, the spleen index of the experimental group mice was significantly lower than that of the model group. Figure 3 PC@PEG-PLLA NPs significantly reduced the levels of ALT and AST in Con A-induced AIH mice. Figure 4 shown.

[0093] (6) Hematoxylin-eosin staining (HE staining).

[0094] Twelve hours after administration, the abdominal cavity of the mice was opened, and the liver tissue was taken for routine hematoxylin-eosin (HE) staining. After sealing with neutral resin, the degree of inflammatory response of the mouse liver was observed under an optical microscope.

[0095] Experimental results: The liver cells of the mice in the model group were obviously necrotic, which was in sharp contrast to the mice in the blank group. The nuclei of the necrotic liver cells in the lesions disappeared, the cell membrane dissolved, and the cytoplasm was light pink granular. In addition, lymphocyte infiltration was visible around. Compared with the model group, the area of ​​liver cell necrosis in the treatment group was reduced, and the number of infiltrating inflammatory cells decreased. These findings indicate that the PC@PEG-PLLA nanoparticle experimental group has the potential to reduce the severity of liver cell necrosis. The results are as follows Figure 5 shown.

[0096] The specific embodiments described herein are merely examples of the spirit of the present invention. Those skilled in the art may make various modifications or additions to the specific embodiments described or replace them in similar ways, but they will not deviate from the spirit of the present invention or exceed the scope defined by the appended claims.

Claims

1. A nanoparticle composition of Pholiotaepus extract, characterized in that: The nanoparticle composition includes core filling PC, carrier material, surfactant, emulsifier and water. The average particle size of the nanoparticle composition is 113.1±2.5nm, the polydispersity index PDI is 0.173±0.020, and the potential is -46.7±1.9mV. The mass ratio of core filling PC to carrier material is 1:

3.

2. The nanoparticle composition of Pholiota mume extract according to claim 1, characterized in that: The carrier material is polyethylene glycol-polylactic acid, which is prepared by mixing L-LA, PEG and stannous octoate in a molar ratio of 100:1:

1.

3. The nanoparticle composition of Photinia scoparia extract according to claim 1, characterized in that: The water is distilled water as a solvent.

4. The nanoparticle composition of Pholiota mume extract according to claim 1, characterized in that: The surfactant is selected from a mixture of one or more of Span20, Span40, Span60, Span80 and Span85.

5. The nanoparticle composition of Pholiota mume extract according to claim 1, characterized in that: The emulsifier is an O / W type emulsifier, selected from one or more of sodium dodecyl sulfate (SDS), Tween 80, and Poloxamer 188.

6. The nanoparticle composition of Photinia scoparia extract according to claim 1, characterized in that: The preparation process of PC core filling material includes the following steps: (1) extracting the medicinal material of Plectranthus radiata with 40-80% by weight ethanol by reflux, heating at about 55° C., refluxing for 2-3 hours, and concentrating the extract at 60-70° C. by rotary evaporation to obtain a crude extract; (2) adding an appropriate amount of water to the extracted extract, mixing, adding an equal volume of petroleum ether, shaking, extracting 3-5 times, evaporating and concentrating to dryness to obtain a petroleum ether partial extract; adding an equal volume of ethyl acetate, shaking, extracting 3-5 times, evaporating and concentrating to dryness to obtain an extract; (3) The ethyl acetate extract was appropriately dissolved in dichloromethane reagent, stirred and ground with 200-300 mesh silica gel particles to form a fine powder, and dry-loaded on a silica gel column, and eluted with a gradient of dichloromethane-methanol eluent with a volume ratio of 50:1, a volume ratio of dichloromethane-methanol eluent with a volume ratio of 10:1, and a volume ratio of dichloromethane-methanol eluent with a volume ratio of 4:1; (4) Take out an appropriate amount of the target fraction, dissolve it in an appropriate amount of dichloromethane, mix it with 200-300 mesh silica gel particles, stir it, and dry-load it onto a silica gel column. Use a petroleum ether-acetone eluent with a volume ratio of 3:1, a petroleum ether-acetone eluent with a volume ratio of 2:1, and a petroleum ether-acetone eluent with a volume ratio of 1:1 to elute in sequence. Then, use a dichloromethane-methanol gradient eluent with a volume ratio of 30:1 to obtain the Pholiotaemum extract PC.

7. A method for preparing the Pholiota mume extract nanoparticle composition according to any one of claims 1 to 6, characterized in that: The following steps are involved: (1) an appropriate amount of L-LA was recrystallized from ethyl acetate 3-5 times, and polyethylene glycol-polylactic acid polymer was prepared by ring-opening polymerization using PEG as an initiator and stannous octoate as a catalyst; (2) PC was dissolved in anhydrous ethanol, polyethylene glycol-polylactic acid polymer was dissolved in dichloromethane, and then 1 drop of Span80 was added; The mixture of the PC solution and the above-mentioned solution containing the polyethylene glycol-polylactic acid polymer is placed in a high-speed shear dispersing emulsifier to ensure complete emulsification; (3) gradually adding the crude emulsified mixture into the SDS solution, and further treating the emulsified mixture with an ultrasonic cell disruptor; (4) stirring the mixed solution with a magnetic force at room temperature until the organic solvent is completely evaporated and solidified to form a Pholiotaepina extract nanoparticle composition.

8. The method for preparing the Pholiota mume extract nanoparticle composition according to claim 7, characterized in that: In step (1), under nitrogen protection, the mixture is heated and polymerized in an oil bath at 100-160° C. for 2-5 hours.

9. The method for preparing a Pholiota mume extract nanoparticle composition according to claim 7, characterized in that: The high-speed shearing in step (2) is operated at a rotation speed of 10000-28000 rpm for 3-5 minutes.

10. The method for preparing the Pholiota mume extract nanoparticle composition according to claim 7, characterized in that: In step (3), the concentration of the SDS solution is 0.5%-5% by mass, and the power of the ultrasonic cell disruptor is 30%-50%.

Images